UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $137
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $135 to $137.
December 07, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS has maintained a Neutral rating on Quest Diagnostics and raised the price target to $137, indicating a potential for limited stock price movement.
The adjustment in price target by UBS is marginal, suggesting a modestly positive outlook without a significant change in valuation. As the rating remains Neutral, the impact on the stock price is likely to be minimal in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100